000			03593nam a22003855i 4500
001			85988
003			ES-MaUEC
005			20230207040537.0
007			cr nn 008mamaa
008			160817s2016 gw | s |||| 0|eng d
020			_a9783319331980
040			_aES-MaUEC
050		4	_aRC643 _b2016 EB
082	0	4	_a616.15
245	1	0	_aChronic Myeloid Leukemia _cedited by Rüdiger Hehlmann
260			_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (X, 255 páginas) _b40 ilustraciones, 39 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aHematologic Malignancies _x2197-9766
505	0		_aCytogenetics of CML -- The biology and pathogenesis of CML -- The choice of 1st line CML-treatment -- A review and up-date of the European LeukemiaNet recommendations for the management of CML -- Management of adverse events associated with ATP-competitive BCR-ABL 1 tyrosine kinase inhibitors in CML -- Standardization of molecular monitoring for CML -- Epidemiology of CML -- Prognostic scores for patients with CML under particular consideration of disease specific death -- Response-related predictors of survival -- CML- blast crisis: implications and management -- Chronic Myeloid Leukemia and Pregnancy -- The role of hematopoietic stem cell transplantation in CML -- Discontinuation or cessation of tyrosine kinase inhibitor treatment in CML patients with deep molecular response -- The interferon-alpha revival in CML -- Changing the cost of care for CML: the availability of generic imatinib.
520	3		_aThis book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon Ü in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib. .
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aMedicina _0comprobar BNE19900959047 _2embne _9405021
650		7	_9140122 _aHematología _0comprobar BNE19900981064 _2embne
700	1		_aHehlmann, Rüdiger _eeditor literario _0Local _999346
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-33198-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319331980
907			_a.b12952667 _b10-10-17 _c21-11-16
988			_aSpringer_Medicine_2016
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aRC643 .C476 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11595309 _z06-04-17
999			_c85988 _d85988 _x1